Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 17, 2008. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the reinvestment of dividends paid on July 10, 2008.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share purchase transactions.
Transaction details include:
- Ordinary Shares Purchase Price: £12.13 per share.
- Ordinary Share ADRs Purchase Price: $47.89 per ADR.
- Transaction Date: July 14, 2008.
Material Changes
The filing reports an increase in share interests for various executives and directors following the dividend reinvestment. No material changes to the company's financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of shares and ADRs purchased by each named individual to assess total insider accumulation.
- Confirm the dividend reinvestment plan terms applicable to the July 10, 2008 dividend payment.
- Check subsequent filings to ensure all required disclosures for the named individuals were completed.